CAR T Therapy Moves Beyond Major Medical Centers: Kite and BBG Advance Mobile Leukapheresis Collection

For patients receiving CAR T-cell therapy, the treatment journey often begins with something that appears technical: collecting their own immune cells. If this step requires long-distance travel to a major medical center, it can already be a heavy barrier for patients who are physically weak, live in remote areas, or have limited caregiving resources.

BBG Advanced Therapies, part of BioBridge Global, announced that it will work with Kite, a Gilead cell therapy company, to deploy a mobile leukapheresis center, with the goal of bringing the cell collection needed for CAR T-cell therapy closer to patients’ communities. Oncodaily’s report on the collaboration also frames it in the context of “bringing CAR T-cell therapy closer to patients.”

Leukapheresis is the starting point for many autologous cell therapies. In CAR T, for example, the medical team first separates T cells from the patient’s blood, then sends them into a manufacturing process for genetic modification and expansion, before finally infusing them back into the patient’s body to attack cancer cells. As a result, collection quality, process consistency, and logistics coordination can all affect subsequent manufacturing and treatment arrangements.

On its mobile leukapheresis center page, BBG Advanced Therapies says this is a mobile collection center designed to expand access to cell and gene therapies, and describes it as using collection processes aligned with the spirit of cGMP, designed and operated by a team with more than 15 years of apheresis experience, and offering a wheelchair-accessible environment. These statements come from company materials; actual operational performance still needs to be tested through collection success rates, patient experience, and manufacturing handoff records in clinical settings.

The program is currently focused on San Antonio and surrounding areas in South Texas, including Laredo, Rio Grande Valley, Eagle Pass, Del Rio, and Victoria. For patients in these areas, if collection can be completed in a closer setting, it may reduce the pressures of transportation, lodging, and caregiving arrangements. However, CAR T treatment itself still involves highly specialized evaluation, manufacturing, lymphodepleting chemotherapy, infusion, and toxicity monitoring, and mobile collection does not mean the full treatment can be completed entirely in the community.

BioBridge Global describes Kite as an important company in the cell therapy field. The significance of this collaboration lies in pushing the “decentralization” long discussed by industry toward the earlier part of the treatment process: not immediately changing the CAR T manufacturing model, but first bringing the key collection step closer to patients. BBG Advanced Therapies also says its platform can support FDA-approved autologous and allogeneic cell therapies, as well as decentralized or hybrid clinical trials. However, publicly available information does not provide the specific products, patient numbers, launch timeline, or performance indicators covered by this collaboration.

If this type of mobile model is to expand, regulatory and quality systems will be central issues. Cell collection is not like ordinary specimen collection; it involves identity verification, aseptic processes, chain of custody, temperature control, and handoff documentation. An error in any link could affect subsequent manufacturing or patient safety. Therefore, the real test is not only whether the vehicle and equipment can move, but whether, after moving, the process can still maintain the same traceability and stability as a fixed center.